Attovia Therapeutics (ATTO) closed at $15.27 on November 6, 2026, up 1.8% from the previous close, on volume of 212,438 shares (30-day average 393,286).
Data as of November 6, 2026.
No headlines found.
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Attovia Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 27-Oct 4:05 PM ET)
Globe Newswire (Mon, 28-Sep 4:05 PM ET)
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Globe Newswire (Wed, 2-Sep 4:05 PM ET)
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
Attovia Therapeutics trades on the NASDAQ stock market under the symbol ATTO.
As of November 6, 2026, ATTO stock price climbed to $15.27 with 212,438 million shares trading.
ATTO has a beta of -0.85, meaning it tends to be less sensitive to market movements. ATTO has a correlation of 0.01 to the broad based SPY ETF.
ATTO has a market cap of $697.09 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ATTO belongs to (by Net Assets): VTI, VXF, SCHA, VTWO, SCHB.
ATTO support price is $14.11 and resistance is $15.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATTO shares will trade within this expected range on the day.
